Subtype
Pancreatic Neoplasm
CI-CAN-00001356Explore in graph →
Non-malignant987 active trials8 approved drugs63 evidence items
Loading cancer entity…
Subtype
CI-CAN-00001356Explore in graph →
Clinical trials
4,216 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06144762 | Precision Imaging for Early Detection and Targeted Treatment Monitoring in Pancreatic Cancer(PANC-O-MICS) | recruiting | N/A | 150 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 1 | Feb 12, 2025 | clinicaltrials |
| NCT05737953 | Construction of Molecular Diagnostic Marker Model for Pancreatic Cystic Tumors Based on Pancreatic Cystic Fluid Samples | recruiting | — | 100 | Zhaoshen LiOTHER | 1 | Feb 11, 2025 |
| clinicaltrials |
| NCT05880472 | Percutaneous Holmium Injection in Pancreatic Cancer(SLOTH-2a) | active not recruiting | N/A | 6 | Radboud University Medical CenterOTHER | 1 | Feb 11, 2025 | clinicaltrials |
| NCT06819215 | Phase I/II Clinical Study to Evaluate VB15010 Tablets in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 188 | Zhejiang Yangli Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Feb 11, 2025 | clinicaltrials |
| NCT06139042 | Early-stage Detection of LIver, Biliary TRAct and PancReatic Cancers | recruiting | — | 1,608 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Feb 10, 2025 | clinicaltrials |
| NCT06750861 | QL1706 Plus Chemotherapy With AG Regime as First-line Treatment of Advanced PDAC | not yet recruiting | Phase 2 | 30 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Feb 10, 2025 | clinicaltrials |
| NCT06782412 | Multicenter Validation Trial of [18F]AlF-FAPI-74 for PET Imaging of Cancer-associated Fibroblasts Through Fibroblast Activation Protein Inhibitors (FAPI) in Different Tumor Types(FAPIDO) | recruiting | Phase 2 / Phase 3 | 109 | KU LeuvenOTHER | 1 | Feb 7, 2025 | clinicaltrials |
| NCT06815172 | PARA (Pancreatic Adenocarcinoma Etiology: Role of Asbestos) Study of Risk Factors for Exocrine Pancreatic Neoplasms.(PARA) | active not recruiting | — | 500 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Feb 7, 2025 | clinicaltrials |
| NCT06427447 | Adjuvant Chemoradiotherapy Versus Chemotherapy for Pancreatic Cancer (ADJUPANC)(ADJUPANC) | recruiting | Phase 3 | 770 | Changhai HospitalOTHER | 1 | Feb 4, 2025 | clinicaltrials |
| NCT06807112 | The Influence of Secretin Stimulated Pancreatic Secretion on ctDNA Expression in Patients With Pancreatic Ductal Adenocarcinoma: The Role of Biomarkers in Determining the Prognosis of Pancreatic Ductal Adenocarcinoma | not yet recruiting | — | 39 | Charles University, Czech RepublicOTHER | 1 | Feb 4, 2025 | clinicaltrials |
| NCT06387342 | Namodenoson Treatment of Advanced Pancreatic Cancer | recruiting | Phase 2 | 20 | Can-Fite BioPharmaINDUSTRY | 1 | Jan 31, 2025 | clinicaltrials |
| NCT06789679 | Albumin-Bound Paclitaxel and Gemcitabine With or Without S-1 as First-Line Treatment for Advanced Pancreatic Cancer | recruiting | Phase 2 | 128 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jan 30, 2025 | clinicaltrials |
| NCT06800469 | Gut Microbiota Analysis in Patients Undergoing Duodencephalopancreasectomy for Pancreatic Cancer | recruiting | N/A | 30 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Jan 30, 2025 | clinicaltrials |
| NCT05841420 | Gemcitabine Versus Reduced-dose Combination Chemotherapy in Fragile Patients with Non-resectable Pancreatic Cancer | recruiting | Phase 2 | 98 | Morten LadekarlOTHER | 1 | Jan 29, 2025 | clinicaltrials |
| NCT04986930 | mFOLFIRINOX With or Without Stereotactic Body Radiotherapy in Locally Advanced Pancreatic Adenocarcinoma(SABER) | active not recruiting | Phase 2 | 92 | Asan Medical CenterOTHER | 1 | Jan 28, 2025 | clinicaltrials |
| NCT06774170 | Structured Follow-up Intervention on Glucose Status After Pancreatic Cancer Surgery(FiGluR) | enrolling by invitation | N/A | 40 | Dokuz Eylul UniversityOTHER | 1 | Jan 23, 2025 | clinicaltrials |
| NCT05562297 | Neoadjuvant/Adjuvant Sintilimab, Nab-paclitaxel, and Gemcitabine for Resectable/Borderline Resectable Pancreatic Cancer | not yet recruiting | Phase 2 | 50 | Shanghai Zhongshan HospitalOTHER | 1 | Jan 22, 2025 | clinicaltrials |
| NCT06787807 | Proteomic Analysis of Patients Undergoing Bariatric Surgery | not yet recruiting | N/A | 103 | Universidade Federal de PernambucoOTHER | 1 | Jan 22, 2025 | clinicaltrials |
| NCT06782555 | A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab | recruiting | Phase 1 / Phase 2 | 71 | ImmunoGenesisINDUSTRY | 1 | Jan 21, 2025 | clinicaltrials |
| NCT06782685 | Liposomal Irinotecan + Oxaliplatin + Bevacizumab Versus Liposomal Irinotecan + 5-FU/LV | recruiting | Phase 1 / Phase 2 | 138 | Dai, GuanghaiOTHER | 1 | Jan 20, 2025 | clinicaltrials |
| NCT06777030 | Role of Exosomes in Pancreatic Cancer Progression | recruiting | — | 60 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Jan 15, 2025 | clinicaltrials |
| NCT06572813 | Bortezomib Combined with PD-1 MAb and MFOLFIRINOX for Metastatic Pancreatic Cancer(CISPD-7) | recruiting | Phase 1 / Phase 2 | 63 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Jan 10, 2025 | clinicaltrials |
| NCT06592989 | A Clinical Study of Sorafenib Combined With Gefitinib for the Treatment of pNET | recruiting | — | 20 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Jan 10, 2025 | clinicaltrials |
| NCT06766019 | Adebrelimab Combined With Irinotecan Liposomal (II), Oxaliplatin, and 5-FU/LV Conversion Therapy for Locally Advanced Pancreatic Cancer | active not recruiting | Phase 2 | 47 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jan 9, 2025 | clinicaltrials |
| NCT04404595 | Claudin18.2 CAR-T (CT041) in Patients With Gastric, Pancreatic Cancer, or Other Specified Digestive Cancers | active not recruiting | Phase 1 / Phase 2 | 110 | CARsgen Therapeutics Co., Ltd.INDUSTRY | 2 | Jan 8, 2025 | clinicaltrials |
| NCT06764134 | Assessing Pancreatic Fistula Rates After Distal Pancreatectomy Using AEON Endostapler(AEON-DP) | recruiting | — | 110 | University Hospital HeidelbergOTHER | 1 | Jan 8, 2025 | clinicaltrials |
| NCT03368963 | TAS102 in Combination With NAL-IRI in Advanced GI Cancers | active not recruiting | Phase 1 / Phase 2 | 64 | Emory UniversityOTHER | 1 | Jan 7, 2025 | clinicaltrials |
| NCT06760741 | PREVENPANC Project: a Spanish Multicenter Study for Pancreatic Cancer Prevention(PREVENPANC) | not yet recruiting | — | 900 | Hospital Clinic of BarcelonaOTHER | 0 | Jan 7, 2025 | clinicaltrials |
| NCT06761027 | mFOLFIRINOX Plus Anlotinib and Sintilimab for Advanced Pancreatic Cancer | recruiting | Phase 1 / Phase 2 | 29 | Fujian Provincial HospitalOTHER | 1 | Jan 7, 2025 | clinicaltrials |
| NCT06759090 | Metronomic Capecitabine with Camrelizumab and Apatinib Mesylate for Treatment of Advanced Pancreatic Cancer | not yet recruiting | Phase 2 | 43 | Zhejiang UniversityOTHER | 1 | Jan 6, 2025 | clinicaltrials |
| NCT01954992 | Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer | recruiting | Phase 3 | 480 | Eleison Pharmaceuticals LLC.INDUSTRY | 1 | Dec 31, 2024 | clinicaltrials |
| NCT05218889 | Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer | recruiting | Phase 1 / Phase 2 | 90 | Chinese PLA General HospitalOTHER | 1 | Dec 31, 2024 | clinicaltrials |
| NCT06753318 | Validation of Joint-AI in Diagnosing Pancreatic Solid Lesions | not yet recruiting | N/A | 716 | Huazhong University of Science and TechnologyOTHER | 1 | Dec 31, 2024 | clinicaltrials |
| NCT04827953 | Study to Evaluate the Safety and Efficacy of Treatment With NLM-001 and Standard Chemotherapy Plus Zalifrelimab in Patients With Advanced Pancreatic Cancer(NUMANTIA) | active not recruiting | Phase 1 / Phase 2 | 28 | Nelum CorpINDUSTRY | 1 | Dec 30, 2024 | clinicaltrials |
| NCT05501379 | Comparison of the Physical Activity in Cancer Patients Assessed by Questionnaire and Motion Tracker(OncoPhys) | recruiting | — | 60 | University Medicine GreifswaldOTHER | 1 | Dec 27, 2024 | clinicaltrials |
| NCT06405490 | NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDAC | recruiting | Phase 2 | 30 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Dec 24, 2024 | clinicaltrials |
| NCT06747481 | Neutrophil-to-lymphocyte Ratio and CA 19.9 as Predictors of Perineural Invasion in Pancreatic Cancer | recruiting | — | 323 | University of Las Palmas de Gran CanariaOTHER | 1 | Dec 24, 2024 | clinicaltrials |
| NCT05121038 | CEND-1 in Combination with Neoadjuvant FOLFIRINOX with or Without Panitumumab(CENDIFOX) | active not recruiting | Phase 1 / Phase 2 | 50 | Anup KasiOTHER | 1 | Dec 17, 2024 | clinicaltrials |
| NCT05859750 | A Study of AK104 With Chemotherapy as First-line Treatment in Patients With Advanced Pancreatic Cancer | recruiting | Phase 2 | 78 | AkesoINDUSTRY | 1 | Dec 16, 2024 | clinicaltrials |
| NCT06601010 | The Value of 68Ga-grazytracer PET in Monitoring Responses to Immunotherapy of Pancreatic Cancer. | recruiting | — | 30 | Ruijin HospitalOTHER | 1 | Dec 11, 2024 | clinicaltrials |
| NCT03252808 | Phase I Study of TBI-1401(HF10) Plus Chemotherapy in Patients with Unresectable Pancreatic Cancer. | active not recruiting | Phase 1 | 36 | Takara Bio Inc.INDUSTRY | 1 | Dec 9, 2024 | clinicaltrials |
| NCT05606523 | Microbiota and Pancreatic Cancer Cachexia(EXTRA) | recruiting | — | 24 | Genton Graf LaurenceOTHER | 1 | Dec 6, 2024 | clinicaltrials |
| NCT06148298 | Cell-Free DNA Chromatin Immunoprecipitation (ChIP) for Diagnosing Cancer | recruiting | — | 24 | University of Central FloridaOTHER | 1 | Dec 6, 2024 | clinicaltrials |
| NCT06310993 | Exercise to Boost Immunity in Advanced Cancer(BICEP) | not yet recruiting | N/A | 30 | Sheffield Teaching Hospitals NHS Foundation TrustOTHER | 1 | Dec 3, 2024 | clinicaltrials |
| NCT06714604 | Standard or Prolonged Neoadjuvant Chemotherapy Before Surgery for BR/LAPC(ADVANTAGE) | recruiting | Phase 3 | 432 | Sahlgrenska University HospitalOTHER | 1 | Dec 3, 2024 | clinicaltrials |
| NCT06711211 | Spanish Registry of Digestive Tumours RETUD(RETUD) | recruiting | — | 20,000 | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)OTHER | 1 | Dec 2, 2024 | clinicaltrials |
| NCT05529940 | NeoFOL-R Trial (Perioperative Versus Adjuvnat FOLFIRINOX in Resectable Pancreatic Cancer) | recruiting | Phase 3 | 609 | Seoul National University HospitalOTHER | 1 | Nov 27, 2024 | clinicaltrials |
| NCT06598033 | Vitamin C Plus Cordyceps to Quality of Life in Patients With Terminal Stage Pancreatic Cancer | recruiting | Phase 2 / Phase 3 | 50 | Fudan UniversityOTHER | 1 | Nov 26, 2024 | clinicaltrials |
| NCT06601283 | Vitamin C Plus Cordyceps to Chemotherapy Related Anemia in Pancreatic Cancer | recruiting | Phase 2 / Phase 3 | 50 | Fudan UniversityOTHER | 1 | Nov 26, 2024 | clinicaltrials |
| NCT06703905 | Conventional Partial Pancreatoduodenectomy Versus an Extended Pancreatoduodenectomy for Pancreatic Head Cancers | not yet recruiting | N/A | 270 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 0 | Nov 25, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Feb 12, 2025source: clinicaltrials